Drug Delivery Devices for Cell & Gene Therapy Analysis

According to FutureWise analysis, the market for cell and gene therapy drug delivery devices in 2025 is US$ 1.12 billion, and is expected to reach US$ 2.6 billion by 2033 at a CAGR of 11.10%. The sector is experiencing growth due to the rising use of advanced therapies for genetic disorders, cancers, and rare diseases. There is a growing need for precise delivery systems as researchers develop innovative vectors and microinjection technologies that improve targeted delivery and outcomes. Ongoing R&D investments are also driving the development of next-generation devices optimized for safety and scalability in clinical applications.

Cell and gene therapies (CGTs) are an innovative class of medical treatments designed to address diseases by introducing, removing, or modifying genetic material within patient cells. Unlike conventional small-molecule drugs or biologics, CGTs operate as living therapeutics, which include autologous or allogeneic cells, viral vectors, or nucleic acids. These treatments necessitate precise, safe, and efficient delivery mechanisms to ensure that therapeutic agents reach the targeted tissues effectively. This need has led to the development of specialized drug delivery devices tailored for cell and gene therapies, which help ensure that therapeutic payloads achieve accurate anatomical location, adequate transduction or engraftment, and reduced off-target effects or immune reactions.

These delivery systems encompass various technologies, including minimally invasive catheters, microneedle arrays, implantable bioreactors, and microfluidic platforms. For instance, intramyocardial injection catheters equipped with deflectable tips facilitate the direct delivery of cardiosphere-derived cells or adeno-associated virus (AAV) vectors into ischemic heart tissue during minimally invasive procedures. In oncology, electroporation devices like the Cliniporator are used to administer controlled electrical pulses, enhancing the uptake of plasmid DNA in solid tumors. Ocular gene therapies utilize subretinal cannulas designed for micro-volume accuracy, enabling the precise delivery of AAV2 vectors beneath the retina while protecting sensitive areas such as the fovea. Additionally, ex vivo platforms like the Miltenyi CliniMACS Prodigy streamline the automation of CAR-T cell transduction, washing, and formulation within a closed, Good Manufacturing Practice (GMP)-compliant system, effectively merging device use with manufacturing processes.

Regulatory agencies such as the FDA and EMA categorize many of these tools as combination products, which necessitate dual oversight of both the biologic and device components in accordance with regulations like 21 CFR Part 820 and ISO 13485. Significant challenges in this field include scalability, ensuring lot-to-lot consistency, and minimizing shear stress during infusion, which can compromise cell viability. Recent advancements in biomaterials, such as heparin-coated tubing and biodegradable scaffolds, are being developed to mitigate the risks associated with immunogenicity and thrombosis.

FutureWise Market Research has published a report that provides an insightful analysis of Cell and Gene Therapy Drug Delivery Devices Market trends that are affecting the overall market growth.

Request a Free Sample @ https://www.futurewiseresearch.com/contact.aspx?rpt=11726&type=requestsample

Cell and Gene Therapy Drug Delivery Devices Market Segmentation:

By Product Type

• Subretinal Injection Cannula
• Extension Tube
• Intravenous Catheter
• Sterile Insulin Syringe
  • Sterile Insulin Syringe (Size 1.0 ML, 31-Gauge Needle)
  • Sterile Insulin Syringe (Size 0.5 ML, 22 Gauge Needle)
• Pre-Filled Syringe
  • Pre-Filled Syringe (Size 1.0 ML, 22-26 Gauge Needle)
  • Pre-Filled Syringe (Size 4.0 ML, 22-26 Gauge Needle)
• Infusion Bags
  • Infusion Bags (Size 10 ML to 50 ML)
  • Infusion Bags (Size 68 ML)
  • Infusion Bags (Size 60 ML)
  • Infusion Bags (Size Up to 65 ML)

By Commercialized Drugs

• Luxturna
• Kymriah
• Yescarta
• Zolgensma
• Provenge
• Strimvelis

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Competitive Landscape in Cell and Gene Therapy Drug Delivery Devices Market:

• Amgen, Inc.
• Bausch & Lomb Incorporated
• Becton, Dickinson and Company
• Bluebird Bio, Inc.
• Castle Creek Biosciences, Inc (Fibrocell Technologies, Inc.)
• Dendreon Pharmaceuticals LLC.
• Helixmith Co., Ltd (ViroMed Co., Ltd)
• Human Stem Cell Institute
• Kite Pharma, Inc.
• Novartis AG
• Kolon Tissue Gene, Inc.
• Orchard Therapeutics plc.
• Pfizer, Inc.
• Renova Therapeutics
• Spark Therapeutics, Inc.
• UniQure N.V.
• Vericel Corporation

Buy now the latest version of this report: https://www.futurewiseresearch.com/checkout.aspx?ReportId=11726&license=multi

**Objectives of this Study: **

1. To provide a comprehensive analysis of the Cell and Gene Therapy Drug Delivery Devices Market By Product Type, By Commercialized Drugs and By Region.
2. To offer detailed insights into factors such as drivers, restraints, trends, and opportunities, as well as segmental and regional influences on market growth.
3. To evaluate current market trends and forecast micro-markets, presenting overall market projections in the form of data sets and PowerPoint presentations.
4. To predict the market size in key regions, including North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

                                                                                                                
Flexible Delivery Model:

• We have a flexible delivery model and you can suggest changes in the scope/table of contents as per your requirement
• The customization services offered are free of charge with the purchase of any license of the report.
• You can directly share your requirements/changes to the current table of contents to: sales@futurewiseresearch.com

Article source: https://article-realm.com/article/Health-Fitness/78552-Drug-Delivery-Devices-for-Cell-and-Gene-Therapy-Analysis.html